View Future GrowthGubra 過去の業績過去 基準チェック /06Gubraの収益は年間平均-78.4%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.8% 2.7%割合で 増加しています。主要情報-78.39%収益成長率-127.66%EPS成長率Life Sciences 業界の成長21.51%収益成長率2.74%株主資本利益率-8.10%ネット・マージン-13.73%次回の業績アップデート21 Aug 2025最近の業績更新お知らせ • Feb 19+ 1 more updateGubra A/S to Report First Half, 2026 Results on Aug 20, 2026Gubra A/S announced that they will report first half, 2026 results on Aug 20, 2026お知らせ • Feb 27+ 1 more updateGubra A/S to Report First Half, 2025 Results on Aug 21, 2025Gubra A/S announced that they will report first half, 2025 results on Aug 21, 2025すべての更新を表示Recent updatesお知らせ • Mar 04Gubra A/S, Annual General Meeting, Mar 26, 2026Gubra A/S, Annual General Meeting, Mar 26, 2026, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, 2970, Denmarkお知らせ • Feb 19+ 1 more updateGubra A/S to Report First Half, 2026 Results on Aug 20, 2026Gubra A/S announced that they will report first half, 2026 results on Aug 20, 2026お知らせ • Jan 08Amylyx Pharmaceuticals, Inc. Announces Nomination of Amx0318 as A Novel, Long-Acting Glp-1 Receptor AntagonistAmylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S. AMX0318 has completed extensive preclinical evaluation, including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and in vivo tolerability studies. Amylyx expects the program to advance into investigational new drug (IND)-enabling studies later this year, with an IND targeted for 2027, pending successful completion of IND-enabling studies. Under the terms of the research collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestones plus mid-single digit royalties on worldwide net sales. The selection and handover of the development candidate will provide milestone payments of $4 million to Gubra.お知らせ • Jan 05Gubra Announces Executive ChangesGubra announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO) effective January 5, 2026. Dr. Langenickel brings more than two decades of experience in big pharma and biotech, spanning drug discovery, translational medicine, and clinical development. In his new role, he will join Gubra’s Leadership Team and guide the company’s preclinical and clinical development strategy as its pipeline advances toward key milestones. Dr. Langenickel most recently served as Chief Medical Officer at Ethris, where he led the development of early clinical assets in respiratory and infectious diseases. His prior experience includes senior roles at Novartis as Executive Director of Translational Medicine and Profiling, and at Bristol Myers Squibb as Medical Director. He earned his M.D. from Humboldt University of Berlin and completed a postdoctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH (USA). Gubra also extends its gratitude to Dr. Mads Axelsen, who retired in December after serving as CMO. His leadership and contributions have been instrumental in shaping Gubra's development organization and supporting the company's growth.お知らせ • Jun 27Gubra A/S Approves Distribution of Extraordinary Cash DividendsGubra A/S at its EGM held on June 27, 2025, approved a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1 billion, corresponding to DKK 61.2 per share of a nominal value of DKK 1.お知らせ • Jun 03Gubra A/S Proposes Extraordinary Cash DividendGubra A/S board of directors proposed that the extraordinary general meeting to be held on 27 June 2025, approves a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1,000 million, corresponding to DKK 61.2 (rounded) per share of a nominal value of DKK 1.お知らせ • Apr 04Gubra A/S Approves Board ChangesGubra A/S in its annual general meeting held on 3 April, 2025, Henriette Dræbye Rosenquist did not stand for re-election. The Board extends heartfelt Henriette for her significant contributions wishing her all the best in her new endeavours. The Board welcomes Gubra Co-Founder and Scientific Advisor Niels Vrang's re-entry to the board and Claudia Mitchell as new members of the Board. Their collective experience in biotech innovation, research, and entrepreneurship will be a valuable asset to the next chapters in the company's growth journey. Monika Lessl, previously serving as a Board member, has been appointed as the new Chair, succeeding Jacob Jelsing, who remains an active member of the Board. As internationally experienced pharma and life science executive with more than 25 years of R&D and Innovation leadership, Monika brings visionary leadership and deep insight into innovation and sustainability - two key pillars of Gubra's mission.お知らせ • Mar 11Gubra A/S, Annual General Meeting, Apr 03, 2025Gubra A/S, Annual General Meeting, Apr 03, 2025, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, dk-2970, horsholm, Denmarkお知らせ • Mar 10Gubra A/S Announces Board ChangesGubra A/S announced Henriette Dræbye Rosenquist does not stand for re-election. The board of directors notes that Jacob Jelsing will step down as chair of the board of directors in connection with the annual general meeting but will continue to serve as an ordinary member of the board of directors.お知らせ • Feb 27+ 1 more updateGubra A/S to Report First Half, 2025 Results on Aug 21, 2025Gubra A/S announced that they will report first half, 2025 results on Aug 21, 2025お知らせ • Jan 15Gubra Appoints Anne-Marie Levy Rasmussen as Chief Operating OfficerGubra announced the appointment of Anne-Marie Levy Rasmussen as the company's new Chief Operating Officer (COO). Anne-Marie brings a strong international experience and track record from global pharma companies such as GlaxoSmithKline and Bavarian Nordic within operational leadership, scaling and establishment of solid governance routines in complex settings. Most recently as Head of Global Commercial Operations at Bavarian Nordic. As COO in Gubra, Anne-Marie will be member of the Executive Management Team and be responsible for overseeing the company's operational strategy, optimizing processes, and driving efficiency across departments and key projects. Her extensive background within leadership, scaling and system integration with new digital approaches positions her well to contribute to Gubra's continued growth and innovation. Anne-Marie's theoretical background is a MSc Physics from University of Copenhagen.収支内訳Gubra の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:GUBR.F 収益、費用、利益 ( )DKK Millions日付収益収益G+A経費研究開発費31 Dec 24266-3610211330 Sep 24245-429410530 Jun 24224-47869731 Mar 24214-46809331 Dec 23205-45758930 Sep 23204-26738330 Jun 23204-7717731 Mar 23201-1696731 Dec 221994675731 Dec 2125568522731 Dec 20172134534質の高い収益: GUBR.Fは現在利益が出ていません。利益率の向上: GUBR.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: GUBR.Fは利益が出ておらず、過去 5 年間で損失は年間78.4%の割合で増加しています。成長の加速: GUBR.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: GUBR.Fは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 3.8% ) と比較することは困難です。株主資本利益率高いROE: GUBR.Fは現在利益が出ていないため、自己資本利益率 ( -8.1% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/03 15:55終値2025/05/06 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gubra A/S 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Rune DahlDNB CarnegieJesper IlsøeDNB CarnegieRajan SharmaGoldman Sachs
お知らせ • Feb 19+ 1 more updateGubra A/S to Report First Half, 2026 Results on Aug 20, 2026Gubra A/S announced that they will report first half, 2026 results on Aug 20, 2026
お知らせ • Feb 27+ 1 more updateGubra A/S to Report First Half, 2025 Results on Aug 21, 2025Gubra A/S announced that they will report first half, 2025 results on Aug 21, 2025
お知らせ • Mar 04Gubra A/S, Annual General Meeting, Mar 26, 2026Gubra A/S, Annual General Meeting, Mar 26, 2026, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, 2970, Denmark
お知らせ • Feb 19+ 1 more updateGubra A/S to Report First Half, 2026 Results on Aug 20, 2026Gubra A/S announced that they will report first half, 2026 results on Aug 20, 2026
お知らせ • Jan 08Amylyx Pharmaceuticals, Inc. Announces Nomination of Amx0318 as A Novel, Long-Acting Glp-1 Receptor AntagonistAmylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S. AMX0318 has completed extensive preclinical evaluation, including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and in vivo tolerability studies. Amylyx expects the program to advance into investigational new drug (IND)-enabling studies later this year, with an IND targeted for 2027, pending successful completion of IND-enabling studies. Under the terms of the research collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestones plus mid-single digit royalties on worldwide net sales. The selection and handover of the development candidate will provide milestone payments of $4 million to Gubra.
お知らせ • Jan 05Gubra Announces Executive ChangesGubra announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO) effective January 5, 2026. Dr. Langenickel brings more than two decades of experience in big pharma and biotech, spanning drug discovery, translational medicine, and clinical development. In his new role, he will join Gubra’s Leadership Team and guide the company’s preclinical and clinical development strategy as its pipeline advances toward key milestones. Dr. Langenickel most recently served as Chief Medical Officer at Ethris, where he led the development of early clinical assets in respiratory and infectious diseases. His prior experience includes senior roles at Novartis as Executive Director of Translational Medicine and Profiling, and at Bristol Myers Squibb as Medical Director. He earned his M.D. from Humboldt University of Berlin and completed a postdoctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH (USA). Gubra also extends its gratitude to Dr. Mads Axelsen, who retired in December after serving as CMO. His leadership and contributions have been instrumental in shaping Gubra's development organization and supporting the company's growth.
お知らせ • Jun 27Gubra A/S Approves Distribution of Extraordinary Cash DividendsGubra A/S at its EGM held on June 27, 2025, approved a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1 billion, corresponding to DKK 61.2 per share of a nominal value of DKK 1.
お知らせ • Jun 03Gubra A/S Proposes Extraordinary Cash DividendGubra A/S board of directors proposed that the extraordinary general meeting to be held on 27 June 2025, approves a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1,000 million, corresponding to DKK 61.2 (rounded) per share of a nominal value of DKK 1.
お知らせ • Apr 04Gubra A/S Approves Board ChangesGubra A/S in its annual general meeting held on 3 April, 2025, Henriette Dræbye Rosenquist did not stand for re-election. The Board extends heartfelt Henriette for her significant contributions wishing her all the best in her new endeavours. The Board welcomes Gubra Co-Founder and Scientific Advisor Niels Vrang's re-entry to the board and Claudia Mitchell as new members of the Board. Their collective experience in biotech innovation, research, and entrepreneurship will be a valuable asset to the next chapters in the company's growth journey. Monika Lessl, previously serving as a Board member, has been appointed as the new Chair, succeeding Jacob Jelsing, who remains an active member of the Board. As internationally experienced pharma and life science executive with more than 25 years of R&D and Innovation leadership, Monika brings visionary leadership and deep insight into innovation and sustainability - two key pillars of Gubra's mission.
お知らせ • Mar 11Gubra A/S, Annual General Meeting, Apr 03, 2025Gubra A/S, Annual General Meeting, Apr 03, 2025, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, dk-2970, horsholm, Denmark
お知らせ • Mar 10Gubra A/S Announces Board ChangesGubra A/S announced Henriette Dræbye Rosenquist does not stand for re-election. The board of directors notes that Jacob Jelsing will step down as chair of the board of directors in connection with the annual general meeting but will continue to serve as an ordinary member of the board of directors.
お知らせ • Feb 27+ 1 more updateGubra A/S to Report First Half, 2025 Results on Aug 21, 2025Gubra A/S announced that they will report first half, 2025 results on Aug 21, 2025
お知らせ • Jan 15Gubra Appoints Anne-Marie Levy Rasmussen as Chief Operating OfficerGubra announced the appointment of Anne-Marie Levy Rasmussen as the company's new Chief Operating Officer (COO). Anne-Marie brings a strong international experience and track record from global pharma companies such as GlaxoSmithKline and Bavarian Nordic within operational leadership, scaling and establishment of solid governance routines in complex settings. Most recently as Head of Global Commercial Operations at Bavarian Nordic. As COO in Gubra, Anne-Marie will be member of the Executive Management Team and be responsible for overseeing the company's operational strategy, optimizing processes, and driving efficiency across departments and key projects. Her extensive background within leadership, scaling and system integration with new digital approaches positions her well to contribute to Gubra's continued growth and innovation. Anne-Marie's theoretical background is a MSc Physics from University of Copenhagen.